PH12021550439A1 - O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors - Google Patents
O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitorsInfo
- Publication number
- PH12021550439A1 PH12021550439A1 PH12021550439A PH12021550439A PH12021550439A1 PH 12021550439 A1 PH12021550439 A1 PH 12021550439A1 PH 12021550439 A PH12021550439 A PH 12021550439A PH 12021550439 A PH12021550439 A PH 12021550439A PH 12021550439 A1 PH12021550439 A1 PH 12021550439A1
- Authority
- PH
- Philippines
- Prior art keywords
- glucopyranosidase
- acetamido
- deoxy
- glycoprotein
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862733484P | 2018-09-19 | 2018-09-19 | |
| US201862750000P | 2018-10-24 | 2018-10-24 | |
| PCT/US2019/051661 WO2020061150A1 (en) | 2018-09-19 | 2019-09-18 | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12021550439A1 true PH12021550439A1 (en) | 2021-11-29 |
Family
ID=68073263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12021550439A PH12021550439A1 (en) | 2018-09-19 | 2021-03-02 | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US12180205B2 (https=) |
| EP (1) | EP3853226A1 (https=) |
| JP (2) | JP7606960B2 (https=) |
| KR (1) | KR20210060513A (https=) |
| CN (2) | CN113166137B (https=) |
| AU (1) | AU2019344922B2 (https=) |
| BR (1) | BR112021004739A2 (https=) |
| CA (1) | CA3113009A1 (https=) |
| CL (1) | CL2021000646A1 (https=) |
| CO (1) | CO2021004873A2 (https=) |
| CR (1) | CR20210181A (https=) |
| IL (2) | IL315564A (https=) |
| JO (1) | JOP20210036A1 (https=) |
| MA (1) | MA53648A (https=) |
| MX (1) | MX2021003232A (https=) |
| PE (1) | PE20211591A1 (https=) |
| PH (1) | PH12021550439A1 (https=) |
| SG (1) | SG11202102379XA (https=) |
| TW (1) | TWI863926B (https=) |
| UA (1) | UA130690C2 (https=) |
| UY (1) | UY38376A (https=) |
| WO (1) | WO2020061150A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12180205B2 (en) * | 2018-09-19 | 2024-12-31 | Biogen Ma Inc. | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors |
| EP3643711A1 (en) | 2018-10-24 | 2020-04-29 | Bayer Animal Health GmbH | New anthelmintic compounds |
| WO2022031701A1 (en) * | 2020-08-03 | 2022-02-10 | Biogen Ma Inc. | Crystaline forms of an o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitor |
| KR102533471B1 (ko) * | 2020-11-23 | 2023-05-19 | (주) 메디프론디비티 | O-GlcNAcase 저해 활성을 갖는 화합물 및 이의 용도 |
| WO2025184490A1 (en) | 2024-03-01 | 2025-09-04 | Biogen Ma Inc. | N-[4-fluor-5-[[(2s, 4 r)-4-[(6-methoxy-4-pyrimidinyl)oxy]- 2-methyl-1-pyrrolidinyl] methyl ]-2-thiazolyl]acetamid for use in the treatment of alzheimer disease |
| US12612396B1 (en) | 2024-11-20 | 2026-04-28 | Dewpoint Therapeutics, Inc. | Modulators of beta catenin and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| JP2004520347A (ja) | 2001-01-15 | 2004-07-08 | グラクソ グループ リミテッド | Ｌｄｌ−受容体発現のインデューサーとしてのアリールピペリジンおよびピペラジン誘導体 |
| BRPI0515500A (pt) | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | derivados piridazina para inibição de estearoil-coa-desaturase |
| SG172352A1 (en) | 2008-12-23 | 2011-07-28 | Abbott Lab | Anti-viral compounds |
| JP2013526546A (ja) | 2010-05-13 | 2013-06-24 | アムジエン・インコーポレーテツド | Ｐｄｅ１０阻害剤としてのヘテロアリ−ルオキシヘテロシクリル化合物 |
| EP2780014A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
| US9051269B2 (en) | 2011-11-18 | 2015-06-09 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2013078320A1 (en) | 2011-11-21 | 2013-05-30 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| JP5989805B2 (ja) | 2012-02-10 | 2016-09-07 | コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | メチル基変更酵素の調節物質、組成物及びその使用 |
| WO2013170072A2 (en) | 2012-05-09 | 2013-11-14 | Neurop, Inc. | Compounds for the treatment of neurological disorders |
| WO2014067003A1 (en) | 2012-10-31 | 2014-05-08 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
| MA38341B1 (fr) | 2013-02-11 | 2018-11-30 | Constellation Pharmaceuticals Inc | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
| PT2970272T (pt) | 2013-03-14 | 2019-06-05 | Merck Patent Gmbh | Inibidores de glicosidase |
| US9745305B2 (en) | 2013-03-15 | 2017-08-29 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US9969716B2 (en) | 2013-08-15 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| KR20160100408A (ko) | 2014-01-06 | 2016-08-23 | 리젠 파마슈티컬스 소시에떼 아노님 | 신규한 글루타미나제 저해제 |
| CN105753814A (zh) | 2015-01-01 | 2016-07-13 | 成都贝斯凯瑞生物科技有限公司 | 取代氮杂环衍生物及其应用 |
| US20190359609A1 (en) * | 2016-12-16 | 2019-11-28 | Janssen Pharmaceutica Nv | Bicyclic oga inhibitor compounds |
| EP3555087A1 (en) * | 2016-12-16 | 2019-10-23 | Janssen Pharmaceutica NV | Monocyclic oga inhibitor compounds |
| TWI654978B (zh) | 2017-01-27 | 2019-04-01 | 美商美國禮來大藥廠 | 5－甲基－1,2,4－二唑－3－基化合物 |
| JP7453916B2 (ja) * | 2018-03-14 | 2024-03-21 | バイオジェン・エムエイ・インコーポレイテッド | Ｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グリコピラノシダーゼ阻害剤 |
| US11459324B2 (en) | 2018-03-14 | 2022-10-04 | Biogen Ma Inc. | O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors |
| CA3102903A1 (en) | 2018-06-20 | 2019-12-26 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
| US12180205B2 (en) | 2018-09-19 | 2024-12-31 | Biogen Ma Inc. | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors |
-
2019
- 2019-09-18 US US17/276,502 patent/US12180205B2/en active Active
- 2019-09-18 JP JP2021515045A patent/JP7606960B2/ja active Active
- 2019-09-18 KR KR1020217010451A patent/KR20210060513A/ko not_active Ceased
- 2019-09-18 AU AU2019344922A patent/AU2019344922B2/en active Active
- 2019-09-18 IL IL315564A patent/IL315564A/en unknown
- 2019-09-18 JO JOP/2021/0036A patent/JOP20210036A1/ar unknown
- 2019-09-18 TW TW108133538A patent/TWI863926B/zh active
- 2019-09-18 EP EP19779339.1A patent/EP3853226A1/en active Pending
- 2019-09-18 MA MA053648A patent/MA53648A/fr unknown
- 2019-09-18 CN CN201980060829.1A patent/CN113166137B/zh active Active
- 2019-09-18 SG SG11202102379XA patent/SG11202102379XA/en unknown
- 2019-09-18 WO PCT/US2019/051661 patent/WO2020061150A1/en not_active Ceased
- 2019-09-18 IL IL281514A patent/IL281514B2/en unknown
- 2019-09-18 PE PE2021000333A patent/PE20211591A1/es unknown
- 2019-09-18 CA CA3113009A patent/CA3113009A1/en active Pending
- 2019-09-18 CN CN202411009108.7A patent/CN119219621A/zh active Pending
- 2019-09-18 CR CR20210181A patent/CR20210181A/es unknown
- 2019-09-18 UY UY0001038376A patent/UY38376A/es active IP Right Grant
- 2019-09-18 UA UAA202101992A patent/UA130690C2/uk unknown
- 2019-09-18 MX MX2021003232A patent/MX2021003232A/es unknown
- 2019-09-18 BR BR112021004739-5A patent/BR112021004739A2/pt unknown
-
2021
- 2021-03-02 PH PH12021550439A patent/PH12021550439A1/en unknown
- 2021-03-16 CL CL2021000646A patent/CL2021000646A1/es unknown
- 2021-04-16 CO CONC2021/0004873A patent/CO2021004873A2/es unknown
-
2024
- 2024-05-24 US US18/673,619 patent/US12275728B2/en active Active
- 2024-09-27 JP JP2024168726A patent/JP2025011144A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202102379XA (en) | 2021-04-29 |
| US20240308995A1 (en) | 2024-09-19 |
| IL281514B2 (en) | 2025-02-01 |
| IL281514A (en) | 2021-04-29 |
| JP2022500472A (ja) | 2022-01-04 |
| UY38376A (es) | 2020-04-30 |
| AU2019344922A1 (en) | 2021-03-25 |
| CO2021004873A2 (es) | 2021-07-30 |
| BR112021004739A2 (pt) | 2021-06-01 |
| CN119219621A (zh) | 2024-12-31 |
| JP2025011144A (ja) | 2025-01-23 |
| TWI863926B (zh) | 2024-12-01 |
| US12275728B2 (en) | 2025-04-15 |
| UA130690C2 (uk) | 2026-04-22 |
| CN113166137B (zh) | 2024-08-16 |
| CN113166137A (zh) | 2021-07-23 |
| WO2020061150A1 (en) | 2020-03-26 |
| TW202031651A (zh) | 2020-09-01 |
| EP3853226A1 (en) | 2021-07-28 |
| JOP20210036A1 (ar) | 2021-02-25 |
| CL2021000646A1 (es) | 2021-09-03 |
| US20220041586A1 (en) | 2022-02-10 |
| IL281514B1 (en) | 2024-10-01 |
| AU2019344922B2 (en) | 2025-02-06 |
| IL315564A (en) | 2024-11-01 |
| CA3113009A1 (en) | 2020-03-26 |
| CR20210181A (es) | 2021-07-01 |
| US12180205B2 (en) | 2024-12-31 |
| JP7606960B2 (ja) | 2024-12-26 |
| KR20210060513A (ko) | 2021-05-26 |
| PE20211591A1 (es) | 2021-08-18 |
| MA53648A (fr) | 2021-07-28 |
| MX2021003232A (es) | 2021-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550439A1 (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| WO2019178191A8 (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors | |
| ZA202206923B (en) | New methylquinazolinone derivatives | |
| WO2019165043A3 (en) | Indane-amines as pd-l1 antagonists | |
| SA520411524B1 (ar) | مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها | |
| SA520411222B1 (ar) | مركبات بوصفها معدلات لعامل باديء حقيقي النواة 2ب وتركيبات وطرق | |
| AU2018351533A8 (en) | Crystalline forms and compositions of CFTR modulators | |
| NZ766978A (en) | Atr inhibitor and application thereof | |
| TN2017000521A1 (en) | New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| TN2018000395A1 (en) | New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| GEAP202115057A (en) | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | |
| MX2022004450A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1. | |
| EP4360707A3 (en) | Compositions for treating spinal muscular atrophy | |
| EP4609866A3 (en) | Oxysterols and methods of use thereof | |
| EP4252848A3 (en) | Oxysterols and methods of use thereof | |
| PH12019501639B1 (en) | Jak1 selective inhibitors | |
| AU2018253590A1 (en) | Imidazopyridazine compounds | |
| EP4316591A3 (en) | Oxysterols and methods of use thereof | |
| EP4599887A8 (en) | Oxysterols and methods of use thereof | |
| EA202090978A1 (ru) | Новые макроциклические производные, способ их получения и содержащие их фармацевтические композиции | |
| PH12022551241A1 (en) | Egfr inhibitors | |
| MX2021007247A (es) | Derivados de rapamicina. | |
| PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
| MX379704B (es) | Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida | |
| PH12021550788A1 (en) | New amino-pyrimidonyl-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them |